Douglas Hay, Vice President
Douglas Hay is a pharmaceutical executive with more than 20 years of experience in drug discovery with GlaxoSmithKline. Dr. Hay has particular experience with inflammatory disease therapeutics. He was most recently Vice President of the COPD Drug Discovery group within the Respiratory & Inflammation Centre of Excellence for Drug Discovery.
Dr. Hay received his PhD in Physiology and Pharmacology from the University of Strathclyde, Scotland.
Russell Wyborski, Project Manager
Dr. Russell Wyborski has over 25 years of drug discovery and product development experience at Pfizer and Avon Products. His research experience includes work in the neuroscience, cardiovascular, inflammation, and skin biology therapeutic areas.
Dr. Wyborski received his Ph.D. in Biochemistry from Indiana University and completed a Postdoctoral Fellowship in Neurobiology at the Washington University at St. Louis Medical School.
Jeff Edelson, MD, Chief medical officer
Dr. Jeff Edelson has more than 30 years of drug development experience, having served in senior clinical R&D roles for several biotech and pharmaceutical firms including SmithKline Beecham, Therion Biologics, GlaxoSmithKline, Aventis and Johnson and Johnson Pharmaceutical Research and Development, where he was most recently the Therapeutic Area Head of Novel Therapeutics. He has experience developing immuno-oncology products, including cancer vaccines, as well as products for pulmonary, immunology, neurology, and therapeutic oncology across all phases of development.
Dr. Edelson earned his MD at the University of Toronto.